Logo

Bausch Health Launches Trulance (plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation in Canada

Share this

Bausch Health Launches Trulance (plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation in Canada

Shots:

  • The company reported the commercial availability of Trulance for the treatment of IBS-C in Canada & provides a solution to meet the treatment gap for patients with the same indications
  • The results from the 2 clinical trials of Trulance showed a significant patient self-evaluated reduction in IBS disease severity & reduction in IBS symptoms over PBO in clinical studies, 30.2% & 21.5% of patients were overall responders & showed a reduction in abdominal pain & improvement in complete spontaneous bowel movements
  • Additionally, the incidence of SAEs in patients treated with Trulance was low (0.8%) and similar to PBO while 70% of surveyed IBS-C patients reported the complete relieved in its symptoms

Ref: Newswire.Ca | Image: Rmoto Day

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions